This single institution study evaluated differences in 30-day and 90-day mortality after esophagectomy in nearly 1300 patients. 30-day mortality was 2.9%, hospital mortalit was 5.1%, and 90-day mortality was 7%. Late deaths were related to surgery (particularly the occurrence of anastomotic leakage), sudden death, and recurrent cancer. The sensiti
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Esophageal Cancer - Surgery
July 12, 2014
July 12, 2014
A risk model of mortality associated with esophagectomy in Japan was developed using variables identified in the ACS NSQIP program. 30-day and overall surgical mortality rates were 1.2% and 3.4%, and the morbidity rate was 42%. Morbidity was higher after minimally invasive esophagectomy. Mortality was related to difficulty with ADLs, recent smokin
June 22, 2014
This prospective study evaluated the relationship of inflammatory gene polymorphisms and postoperative pneumonia after esophagectomy in 120 pts. One genotype for IL-10 was significantly associated with reduced postoperative serum IL-10 levels and an increased rate of postoperative pneumonia. IL-10 polymorphism was an independent predictor of pneumo
May 27, 2014
This retrospective single institution review assessed the incidence of hiatal hernia after minimally invasive esophagectomy (MIE). Of 114 patients followed, 9 (8%) developed herniation, of whom 5 were symptomatic. All were repaired laparoscopically, except 2 who underwent emergent surgery, with good results.
May 21, 2014
Pts undergoing salvage esophagectomy after definitive chemoradiotherapy were evaluated for perdictors of survival. 5-year survival was 30%, which was related to tumor recurrence rather than residual tumor, complete resection, N status, M status, and dissection of more than 15 nodes. Additional neck dissection was not found to provide additional ben
May 21, 2014
The PORTICO trial has opened to evaluate the Portico Transcatheter Aortic Valve System. This prospective multicenter trial involving up to 40 sites will randomize pts to Portico vs another TAVR valve in the US.